The human HCC derived cell lines HepG2, HepB3 and SNU449 were transfected with miRNA inhibitor at a final concentration of 200 nMOL for 96 h using CombiMag.
This paper shows the efficiency of CombiMag from OZ Biosciences to allow and enhance transfection of hepatocellular carcinoma cell lines with miRNA.article reference: BioMed Research Inter, 2014
Synergistic Effect of MiR-146a Mimic and Cetuximab on Hepatocellular Carcinoma Cells
Suning Huang, Rongquan He, Minhua Rong, Yiwu Dang, and Gang ChenAbstract
Previously, we found that the expression of microRNA-146a (miR-146a) was downregulated in hepatocellular carcinoma (HCC) formalin-fixed paraffin-embedded (FFPE) tissues compared to the adjacent non-cancerous hepatic tissues. In the current study, we have explored the in vitro effect of miR-146a on the malignant phenotypes of HCC cells. MiR-146a mimic could suppress cell growth and increase cellular apoptosis in HCC cell lines HepG2, HepB3 and SNU449, as assessed by spectrophotometry, fluorimetry and fluorescence microscopy, respectively. Furthermore, western blot showed that miR-146a mimic downregulated EGFR, ERK1/2 and stat5 signalings. These effects were less potent compared to that of a siRNA targeting EGFR, a known target gene of miR-146a. Moreover, miR-146a mimic could enhance the cell growth inhibition and apoptosis induction impact of various EGFR targeting agents. The most potent combination was miR-146a mimic with cetuximab, presenting a synergistic effect. In conclusion, miR-146a plays a vital role in the cell growth and apoptosis of HCC cells and inducing miR-146a level might be a critical targeted molecular therapy strategy for HCC.
No comments:
Post a Comment